Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-05 03:31:24 UTC |
---|
Update Date | 2014-12-24 20:25:43 UTC |
---|
Accession Number | T3D2571 |
---|
Identification |
---|
Common Name | Acetaminophen |
---|
Class | Small Molecule |
---|
Description | Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. The excellent tolerability of therapeutic doses of paracetamol (acetaminophen) is a major factor in the very wide use of the drug. The major problem in the use of paracetamol is its hepatotoxicity after an overdose. Hepatotoxicity has also been reported after therapeutic doses, but critical analysis indicates that most patients with alleged toxicity from therapeutic doses have taken overdoses. Importantly, prospective studies indicate that therapeutic doses of paracetamol are an unlikely cause of hepatotoxicity in patients who ingest moderate to large amounts of alcohol. (7). Single doses of paracetamol are effective analgesics for acute postoperative pain and give rise to few adverse effects. (8). Acetaminophen (AAP) overdose and the resulting hepatotoxicity is an important clinical problem. In addition, AAP is widely used as a prototype hepatotoxin to study mechanisms of chemical-induced cell injury and to test the hepatoprotective potential of new drugs and herbal medicines. Because of its importance, the mechanisms of AAP-induced liver cell injury have been extensively investigated and controversially discussed for many years. (9). |
---|
Compound Type | - Amide
- Amine
- Analgesic, Non-Narcotic
- Antipyretic
- Drug
- Food Toxin
- Metabolite
- Organic Compound
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 4'-Hydroxyacetanilide | 4-(Acetylamino)phenol | 4-Acetamidophenol | 4-Acetaminophenol | 4-Hydroxyacetanilide | 4-Hydroxyanilid kyseliny octove | A-Per | A.F. Anacin | Abenol | Abensanil | Abrol | Abrolet | Acamol | Accu-Tap | Acenol | Acephen | Acertol | Aceta Elixir | Aceta Tablets | Acetagesic | Acetalgin | Acetaminofen | Acetaminophen Uniserts | Acetaminophene | Acetamol | Acetofen | Actamin | Actamin Extra | Actamin Super | Actifed Plus | Actimol | Actimol Chewable Tablets | Actimol Children'S Suspension | Actimol Infants' Suspension | Actimol Junior Strength Caplets | Actron | Afebrin | Afebryl | Aferadol | Algesidal | Algina | Algomol | Algotropyl | Allay | alpha-Per | Alpiny | Alpinyl | Alvedon | Amadil | Aminofen | Aminofen Max | Anacin-3 | Anacin-3 Extra Strength | Anadin dla dzieci | Anaflon | Analter | Anapap | Andox | Anelix | Anexsia | Anexsia 10/660 | Anexsia 5/325 | Anexsia 7.5/325 | Anexsia 7.5/650 | Anhiba | Anoquan | Anti-Algos | Antidol | Apacet | Apacet Capsules | Apacet Elixir | Apacet Extra Strength Caplets | Apacet Extra Strength Tablets | Apacet Regular Strength Tablets | Apadon | Apamid | Apamide | APAP | Apitrelal | Apo-Acetaminophen | Arfen | Asetam | Asomal | Aspac | Aspirin Free Anacin Maximum Strength Caplets | Aspirin Free Anacin Maximum Strength Gel Caplets | Aspirin Free Anacin Maximum Strength Tablets | Aspirin-Free Anacin | Aspirin-Free Excedrin Caplets | Asplin | Atasol Caplets | Atasol Drops | Atasol Forte Caplets | Atasol Forte Tablets | Atasol Oral Solution | Atasol Tablets | Atralidon | Babikan | Bacetamol | Bancap | Bancap Hc | Banesin | Bayer Select Allergy-Sinus | Bayer Select Head Cold | Bayer Select Headache Pain | Bayer Select Maximum Strength Headache Pain Relief Formula | Bayer Select Menstrual Multi-Symptom | Bayer Select Sinus Pain Relief | Ben-u-ron | Benmyo | Bickie-mol | Biocetamol | Bucet | Butalbital | Butapap | Cadafen | Calapol | Calmanticold | Calpol | Capital with Codeine | Captin | Causalon | Cefalex | Cetadol | Children'S Acetaminophen Elixir Drops | Children'S Acetaminophen Oral Solution | Children'S Tylenol Chewable | Claradol Codeine | Clixodyne | Co-Gesic | Cod-Acamol Forte | Codabrol | Codalgin | Codapane | Codicet | Codisal | Codisal Forte | Codoliprane | Codral Pain Relief | Cofamol | Conacetol | Contac Cough & Sore Throat Formula | Contra-Schmerz P | Coricidin | Coricidin D | Coricidin Sinus | Cosutone | Croix Blanche | Cuponol | Curadon | Curpol | Custodial | Dafalgan | Dapa X-S | Darocet | Darvocet | Darvocet-N 50 | Datril | Datril Extra-Strength | Daygrip | Demilets | Deminofen | Democyl | Demogripal | Desfebre | Dhamol | Dhc Plus | Dial-a-gesic | Dial-alpha-gesic | Dimindol | Dirox | Disprol | Dol-Stop | Dolcor | Dolefin | Dolegrippin | Dolene Ap-65 | Dolgesic | Doliprane | Dolko | Dolofugin | Doloreduct | Dolorfug | Dolorol Forte | Dolorstop | Dolotec | Dolprone | Dorocoff | Dresan | Dristan Cold No Drowsiness | Dristancito | Duracetamol | Duradyne Dhc | Durapan | Dymadon | Dymadon Co | Dymadon Forte | Dypap | Ecosetol | Elixodyne | Empracet | Endecon | Enelfa | Eneril | Esgic | Esgic-Plus | Eu-Med | Excedrin | Excedrin Caplets | Excedrin Extra Strength Caplets | Excipain | Exdol | Exdol Strong | Fanalgic | Farmadol | Febranine | Febrectal | Febrectol | Febrex | Febricet | Febridol | Febrilix | Febrin | Febrinol | Febro-Gesic | Febrolin | Femcet | Fendon | Fensum | Fepanil | Feverall | Feverall Junior Strength | Feverall Sprinkle Caps Junior Strength | Fevor | Finimal | Finiweh | Fioricet | Fluparmol | Fortalidon P | Freka-cetamol | Gattaphen T | Gelocatil | Geluprane | Genapap | Genapap Children'S Elixir | Genapap Children'S Tablets | Genapap Extra Strength Caplets | Genapap Extra Strength Tablets | Genapap Regular Strength Tablets | Genebs | Genebs Extra Strength Caplets | Genebs Regular Strength Tablets | Genebs X-Tra | Geralgine-P | Gripin Bebe | Grippostad | Gynospasmine | Hedex | Helon N | Homoolan | Hy-Phen | Hycomine Compound | Hydrocet | Ildamol | Inalgex | Infadrops | Infants' Feverall | Influbene N | Injectapap | Intensin | Janupap | Junior Disprol | Kataprin | Kinder Finimal | Korum | Kratofin simplex | Labamol | Lekadol | Lemgrip | Lemsip | Lestemp | Liquagesic | Liquigesic Co | Liquiprin | Liquiprin Children'S Elixir | Liquiprin Infants Drops | Lonarid | Lonarid Mono | Lorcet-Hd | Lortab | Lupocet | Lyteca | Lyteca Syrup | Magnidol | Malex N | Malgis | Malidens | Maxadol | Medigesic Plus | Medinol Paediatric | Medocodene | Melabon Infantil | Mexalen | Midol Maximum Strength | Midol PM Night Time Formula | Midol Regular Strength | Midol Teen Formula | Migraleve Yellow | Minafen | Minoset | Miralgin | Momentum | Mono Praecimed | Multin | N-(4-Hydroxyphenyl)acetamide | N-Acetyl-4-aminophenol | N-Acetyl-p-aminophenol | Naldegesic | NAPA | Napafen | Napap | Naprinol | Nealgyl | Nebs | Neo-Fepramol | NeoCitran | Neodol | Neodolito | Neopap | Neotrend | Neuridon | New Cortal for Children | NilnOcen | Nina | No-Febril | Nobedon | Nodolex | Noral | Norcet | Norco | O-Acetaminophenol | Ofirmev | Oltyl | Oralgan | Oraphen-PD | Ortensan | Oxycet | Oxycocet | Oxycodone 2.5/Apap 500 | Oxycodone 5/Apap 500 | p-(Acetylamino)phenol | p-Acetamidophenol | p-Acetaminophenol | p-Acetylaminophenol | p-Hydroxyacetanilide | p-Hydroxyphenolacetamide | Paceco | Pacemo | Pacemol | Pacet | Pacimol | Paedialgon | Paedol | Painex | Paldesic | Pamol | Panacete | Panadeine | Panadeine Co | Panadiene | Panado-Co | Panado-Co Caplets | Panadol | Panadol Extra Strength | Panadol Junior Strength Caplets | Panadol Maximum Strength Caplets | Panadol Maximum Strength Tablets | Panaleve | Panamax | Panasorb | Panasorbe | Panets | Panex | Panodil | Panofen | Pantalgin | Papa-Deine #3 | Papa-Deine #4 | Para-Suppo | Para-Tabs | Paracemol | Paracenol | Paracet | Paracetamol | Paracetamol AL | Paracetamol Antipanin P | Paracetamol Basics | Paracetamol BC | Paracetamol DC | Paracetamol Dr. Schmidgall | Paracetamol Fecofar | Paracetamol Genericon | Paracetamol Hanseler | Paracetamol Harkley | Paracetamol Heumann | Paracetamol Hexal | Paracetamol Italfarmaco | Paracetamol Nycomed | Paracetamol PB | Paracetamol Raffo | Paracetamol Ratiopharm | Paracetamol Rosch | Paracetamol Saar | Paracetamol SmithKline Beecham | Paracetamol Stada | Paracetamol von ct | Paracetamol Winthrop | Paracetamole | Paracetamolo | Paracetamolum | Paracetanol | Paracetol | Paracin | Paracod | Paracodol | Parador | Paradrops | Parakapton | Parake | Paralen | Paralief | Paralink | Paralyoc | Paramol | Paramolan | Paranox | Parapan | Parasedol | Parasin | Paraspen | Parcetol | Parelan | Parmol | Parogal | Paroma | Pasolind | Pasolind N | PCM Paracetamol Lichtenstein | Pe-Tam | Pediapirin | Pediatrix | Pedric | Percocet | Percocet-5 | Percocet-Demi | Percogesic with Codeine | Perdolan Mono | Phenaphen | Phenaphen Caplets | Phenaphen W/Codeine | Phendon | Phenipirin | Phogoglandin | Phrenilin | Phrenilin Forte | Pinex | Piramin | Pirinasol | Plicet | Polmofen | Predimol | Predualito | Prestwick_13 | Prodol | Prompt | Prontina | Propacet | Propacet 100 | Proval #3 | Puernol | Pulmofen | Pyregesic-C | Pyrigesic | Pyrinazine | Pyromed | Quiet World | Redutemp | Reliv | Remedol | Rhinex D-Lay Tablets | Rivalgyl | Robigesic | Robitussin Night Relief | Rockamol Plus | Rounox | Roxicet | Roxicet 5/500 | Roxilox | RubieMol | Rubophen | Rupemol | Salzone | Sanicet | Sanicopyrine | Scanol | Scentalgyl | Scherzatabletten Rezeptur 534 | Schmerzex | Sedalito | Sedapap | Semolacin | Servigesic | Seskamol | Setakop | Setamol | Setol | Sifenol | Sinaspril | Sine-Off Sinus Medicine Caplets | Sinedol | Sinmol | Sinubid | SK-Apap | Snaplets-FR | Spalt fur die nacht | Spalt N | St Joseph Aspirin-Free | St Joseph Aspirin-Free for Children | St. Joseph Cold Tablets for Children | St. Joseph Fever Reducer | Stanback | Stopain | Sudafed Severe Cold Formula | Sudafed Sinus | Sunetheton | Supac | Supadol mono | Supofen | Suppap | Suppap-120 | Suppap-325 | Suppap-650 | Supramol-M | Synalgos-Dc-A | Tabalgin | Tachiprina | Talacen | Tapanol | Tapanol Extra Strength Caplets | Tapanol Extra Strength Tablets | Tapar | Tavist Allergy/Sinus/Headache | Tazamol | Temlo | Tempanal | Tempra | Tempra Caplets | Tempra Chewable Tablets | Tempra D.S | Tempra Drops | Tempra Syrup | Tencon | Termacet | Termalgin | Termalgine | Termofren | TheraFlu | Tibinide | Tibizide | Tiffy | Tisin | Tisiodrazida | Titralgan | Tizide | Tocris-1706 | Toximer P | Tralgon | Treupel mon | Treupel N | Treuphadol | Triad | Triaminic Sore Throat Formula | Triaprin | Tricoton | Tussapap | Tycolet | TYL | Tylenol | Tylenol Allergy Sinus | Tylenol Arthritis Extended Relief | Tylenol Caplets | Tylenol Children'S Chewable Tablets | Tylenol Children'S Elixir | Tylenol Children'S Suspension Liquid | Tylenol Drops | Tylenol Elixir | Tylenol Extra Strength Adult Liquid Pain Reliever | Tylenol Extra Strength Caplets | Tylenol Extra Strength Gelcaps | Tylenol Extra Strength Tablets | Tylenol Gelcaps | Tylenol Infants Drops | Tylenol Infants Suspension Drops | Tylenol Junior Strength Caplets | Tylenol Junior Strength Chewable Tablets | Tylenol Regular Strength Caplets | Tylenol Regular Strength Tablets | Tylenol Tablets | Tylex | Tylex CD | Tylol | Tylox | Tylox-325 | Tymol | Ultracet | Upsanol | Utragin | Valadol | Valgesic | Valorin | Valorin Extra | Vanquish | Veralgina | Vermidon | Verpol | Viclor Richet | Vicodin | Vicodin Es | Vicodin Hp | Vips | Viruflu | Vivimed | Volpan | Wygesic | Zatinol | Zolben |
|
---|
Chemical Formula | C8H9NO2 |
---|
Average Molecular Mass | 151.163 g/mol |
---|
Monoisotopic Mass | 151.063 g/mol |
---|
CAS Registry Number | 103-90-2 |
---|
IUPAC Name | N-(4-hydroxyphenyl)acetamide |
---|
Traditional Name | acetaminophen |
---|
SMILES | CC(O)=NC1=CC=C(O)C=C1 |
---|
InChI Identifier | InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10) |
---|
InChI Key | InChIKey=RZVAJINKPMORJF-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as 1-hydroxy-2-unsubstituted benzenoids. These are phenols that are unsubstituted at the 2-position. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Phenols |
---|
Sub Class | 1-hydroxy-2-unsubstituted benzenoids |
---|
Direct Parent | 1-hydroxy-2-unsubstituted benzenoids |
---|
Alternative Parents | |
---|
Substituents | - 1-hydroxy-2-unsubstituted benzenoid
- Monocyclic benzene moiety
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Carboximidic acid derivative
- Carboximidic acid
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Aromatic homomonocyclic compound
|
---|
Molecular Framework | Aromatic homomonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 169-171°C | Boiling Point | Not Available | Solubility | 1.4E+004 mg/L (at 25°C) | LogP | 0.46 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - GC-MS (2 TMS) | splash10-0a4i-4971200000-17e6e1373f10ba4ec138 | 2014-06-16 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-0a4i-1900000000-df97f74a81da3a46a697 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-0a4i-4900000000-ef277124e1b50b5f010e | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - CI-B (Non-derivatized) | splash10-0udi-0900000000-7aa6a54b74b345d91e37 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - GC-MS (Non-derivatized) | splash10-0a4i-4971200000-17e6e1373f10ba4ec138 | 2017-09-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-3900000000-070b8ab49f93898e0aa4 | 2017-08-28 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (1 TMS) - 70eV, Positive | splash10-05gl-8930000000-76d6dca6afdf5945dba1 | 2017-10-06 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0zfr-0900000000-125e44ce332576a1e155 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-7e46df4b4b653c90c258 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-bb6e34d2d574a249d721 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-2f45dd7efce38361f806 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0pb9-0900000000-e48b48d64b6b985ab455 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0a4i-0900000000-b72b0e33fd35512fe6de | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0a4i-0900000000-97bcaa95f26159307d03 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-c50b4b79792e2c2e68f9 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-7e46df4b4b653c90c258 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-2b07cd2813d3f23e88f1 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0pb9-0900000000-5b92f09589afe838f23a | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0a4i-0900000000-f0ca5ff6526b9f005034 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-ITFT , negative | splash10-0udi-0900000000-7e45ef71674dcdde9068 | 2017-09-14 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 15V, Negative | splash10-0a4i-0900000000-f6d6bd9ad3bc874fabd5 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 35V, Negative | splash10-0a4i-0900000000-7ec733f46e03a5a79fc4 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Negative | splash10-0udi-0900000000-bb6e34d2d574a249d721 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 45V, Negative | splash10-0udi-0900000000-2f45dd7efce38361f806 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Negative | splash10-0udi-0900000000-7e46df4b4b653c90c258 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 35V, Negative | splash10-0zfr-0900000000-125e44ce332576a1e155 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 60V, Negative | splash10-0pb9-0900000000-e48b48d64b6b985ab455 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 75V, Negative | splash10-0a4i-0900000000-b72b0e33fd35512fe6de | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 45V, Negative | splash10-0udi-0900000000-2b07cd2813d3f23e88f1 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 90V, Negative | splash10-0a4i-0900000000-97bcaa95f26159307d03 | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 60V, Negative | splash10-0pb9-0900000000-5b92f09589afe838f23a | 2021-09-20 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 75V, Negative | splash10-0a4i-0900000000-f0ca5ff6526b9f005034 | 2021-09-20 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0a4i-4900000000-ffdd0f8a1e6e450fc162 | 2014-09-20 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, 5%_DMSO, experimental) | Not Available | 2012-12-04 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, DMSO-d6, experimental) | Not Available | 2014-09-20 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 22.53 MHz, DMSO-d6, experimental) | Not Available | 2014-09-23 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Not Available | 2021-09-16 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Not Available | 2012-12-05 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral, rapid and almost complete. |
---|
Mechanism of Toxicity | Paracetamol toxicity is one of the most common causes of poisoning worldwide. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine – also known as NAPQI), not acetaminophen itself nor any of the other major metabolites. Cytochromes P450 2E1 and 3A4 convert approximately 5% of paracetamol to NAPQI. This toxic metabolite reacts with sulfhydryl groups on proteins and with glutathione (GSH). NAPQI depletes the liver's natural antioxidant glutathione and directly damages cells in the liver, leading to liver failure. In animal studies, hepatic glutathione must be depleted to less than 70% of normal levels before hepatotoxicity occurs. More specifically, oxidation by NAPQI of GSH to GSSG (oxidized glutathione) and the reduction of GSSG back to GSH by the NADPH-dependent glutathione reductase appear to be responsible for the rapid oxidation of NADPH that occurs in hepatocytes incubated with NAPQI. Risk factors for toxicity include excessive chronic alcohol intake, fasting or anorexia nervosa, and the use of certain drugs such as isoniazid. At usual doses, paracetamol is quickly detoxified by combining irreversibly with the sulfhydryl group of glutathione to produce a non-toxic conjugate that is eventually excreted by the kidneys. The toxic dose of paracetamol is highly variable. |
---|
Metabolism | Acetaminophen primarily undergoes glucuronidation (45-55% of the dose) in which this process is facilitated by UGT1A1, UGT1A6, UGT1A9, UGT2B15 in the liver or UGT1A10 in the gut. 30-35% of the dose undergoes sulfation. This biotransformation is facilitated by SULT1A1, SULT1A3, SULT1A4, SULT1E1 and SULT2A1. A small percentage of acetaminophen is oxidized by CYP2E1 to form N-acetyl-p-benzo-quinone imine (NAPQI), a toxic metabolite which is then conjugated to glutathione and excreted renally. Studies suggest that CYP3A4 and CYP2E1 are the primary cytochrome P450 isozymes responsible for the generation of toxic metabolites. Accumulation of NAPQI may occur if primary metabolic pathways are saturated. Acetaminophen is metabolized primarily in the liver, where most of it is converted to inactive compounds by conjugation with sulfate and glucuronide, and then excreted by the kidneys. Only a small portion is metabolized via the hepatic cytochrome P450 enzyme system. The toxic effects of acetaminophen are due to a minor alkylating metabolite (N-acetyl-p-benzo-quinone imine), not acetaminophen itself nor any of the major metabolites. This toxic metabolite reacts with sulfhydryl groups. At usual doses, it is quickly detoxified by combining irreversibly with the sulfhydryl group of glutathione to produce a non-toxic conjugate that is eventually excreted by the kidneys. The toxic dose of paracetamol is highly variable.
Route of Elimination: Approximately 80% of acetaminophen is excreted in the urine after conjugation and about 3% is excreted unchanged.
Half Life: 1 to 4 hours |
---|
Toxicity Values | LD50: 338 mg/kg (Oral, Mouse) (1)
LD50: 1944 mg/kg (Oral, Rat) (1)
In adults, single doses above 10 grams or 200 mg/kg of bodyweight, whichever is lower, have a reasonable likelihood of causing toxicity. |
---|
Lethal Dose | 25 g for an adult human. (1) |
---|
Carcinogenicity (IARC Classification) | 3, not classifiable as to its carcinogenicity to humans. (33) |
---|
Uses/Sources | An over-the-counter analgesic (pain reliever) and antipyretic (fever reducer). It is commonly used for the relief of fever, headaches, and other minor aches and pains, and is a major ingredient in numerous cold and flu remedies. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Skin rashes, blood disorders and a swollen pancreas have occasionally happened in people taking the drug on a regular basis for a long time. |
---|
Symptoms | When taken at the recommended dose, side-effects of paracetamol are rare. Skin rashes, blood disorders and a swollen pancreas have occasionally happened in people taking the drug on a regular basis for a long time. The signs and symptoms of paracetamol toxicity occur in three phases. The first phase begins within hours of overdose, and consists of nausea, vomiting, pallor, and sweating. Rarely, after massive overdoses, patients may develop symptoms of metabolic acidosis and coma early in the course of poisoning.The second phase occurs between 24 and 72 hours following overdose and consists of signs of increasing liver damage. In general, damage occurs in hepatocytes as they metabolize the paracetamol. The individual may experience right upper quadrant pain. Acute kidney failure may also occur during this phase, typically caused by either hepatorenal syndrome or multiple organ dysfunction syndrome. The third phase follows at 3 to 5 days, and is marked by complications of massive hepatic necrosis leading to fulminant hepatic failure with complications of coagulation defects, hypoglycemia, kidney failure, hepatic encephalopathy, cerebral edema, sepsis, multiple organ failure, and death. |
---|
Treatment | In adults, the initial treatment for paracetamol overdose is gastrointestinal decontamination. Paracetamol absorption from the gastrointestinal tract is complete within two hours under normal circumstances, so decontamination is most helpful if performed within this timeframe. Gastric lavage, better known as stomach pumping, may be considered if the amount ingested is potentially life-threatening and the procedure can be performed within 60 minutes of ingestion. Acetylcysteine, when used early in the course of treatment, reduces morbidity and virtually eliminating mortality associated with even a massive acetaminophen overdose. (37) In patients who develop fulminant hepatic failure or who are otherwise expected to die from liver failure, the mainstay of management is liver transplantation. |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00316 |
---|
HMDB ID | HMDB01859 |
---|
PubChem Compound ID | 1983 |
---|
ChEMBL ID | CHEMBL112 |
---|
ChemSpider ID | 1906 |
---|
KEGG ID | C06804 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 2386 |
---|
BioCyc ID | CPD-7669 |
---|
CTD ID | D000082 |
---|
Stitch ID | Paracetamol |
---|
PDB ID | TYL |
---|
ACToR ID | 7 |
---|
Wikipedia Link | Acetaminophen |
---|
References |
---|
Synthesis Reference | Jeffrey L. Finnan, Rudolph E. Lisa, Douglass N. Schmidt, “Process for preparing spray dried acetaminophen powder and the powder prepared thereby.” U.S. Patent US4710519, issued October, 1975. |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Kis B, Snipes JA, Busija DW: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther. 2005 Oct;315(1):1-7. Epub 2005 May 6. [15879007 ]
- Aronoff DM, Oates JA, Boutaud O: New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin Pharmacol Ther. 2006 Jan;79(1):9-19. [16413237 ]
- Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S: Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006 Fall-Winter;12(3-4):250-75. [17227290 ]
- Graham GG, Scott KF: Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55. [15662292 ]
- Ohki S, Ogino N, Yamamoto S, Hayaishi O: Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem. 1979 Feb 10;254(3):829-36. [104998 ]
- Graham GG, Scott KF, Day RO: Tolerability of paracetamol. Drug Saf. 2005;28(3):227-40. [15733027 ]
- Barden J, Edwards J, Moore A, McQuay H: Single dose oral paracetamol (acetaminophen) for postoperative pain. Cochrane Database Syst Rev. 2004;(1):CD004602. [14974073 ]
- Jaeschke H: Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):389-97. [16863451 ]
- Jan YH, Heck DE, Dragomir AC, Gardner CR, Laskin DL, Laskin JD: Acetaminophen reactive intermediates target hepatic thioredoxin reductase. Chem Res Toxicol. 2014 May 19;27(5):882-94. doi: 10.1021/tx5000443. Epub 2014 Apr 4. [24661219 ]
- Qiu Y, Benet LZ, Burlingame AL: Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem. 1998 Jul 10;273(28):17940-53. [9651401 ]
- Albano E, Rundgren M, Harvison PJ, Nelson SD, Moldeus P: Mechanisms of N-acetyl-p-benzoquinone imine cytotoxicity. Mol Pharmacol. 1985 Sep;28(3):306-11. [4033631 ]
- Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31. Epub 2002 Sep 19. [12242329 ]
- Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS: Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65. doi: 10.1002/bdra.20535. [18232020 ]
- Hazai E, Vereczkey L, Monostory K: Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun. 2002 Mar 8;291(4):1089-94. [11866476 ]
- Muldrew KL, James LP, Coop L, McCullough SS, Hendrickson HP, Hinson JA, Mayeux PR: Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos. 2002 Apr;30(4):446-51. [11901099 ]
- Bales JR, Nicholson JK, Sadler PJ: Two-dimensional proton nuclear magnetic resonance "maps" of acetaminophen metabolites in human urine. Clin Chem. 1985 May;31(5):757-62. [3987005 ]
- van der Marel CD, Anderson BJ, Pluim MA, de Jong TH, Gonzalez A, Tibboel D: Acetaminophen in cerebrospinal fluid in children. Eur J Clin Pharmacol. 2003 Aug;59(4):297-302. Epub 2003 Jul 4. [12845506 ]
- Watari N, Iwai M, Kaneniwa N: Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats. J Pharmacokinet Biopharm. 1983 Jun;11(3):245-72. [6644552 ]
- Kunkel A, Watzig H: Micellar electrokinetic capillary chromatography as a powerful tool for pharmacological investigations without sample pretreatment: a precise technique providing cost advantages and limits of detection to the low nanomolar range. Electrophoresis. 1999 Sep;20(12):2379-89. [10499329 ]
- Vanbinst R, Koenig J, Di Fazio V, Hassoun A: Bile analysis of drugs in postmortem cases. Forensic Sci Int. 2002 Aug 14;128(1-2):35-40. [12208019 ]
- Quattrone AJ, Putnam RS: A single liquid-chromatographic procedure for therapeutic monitoring of theophylline, acetaminophen, or ethosuximide. Clin Chem. 1981 Jan;27(1):129-32. [7004665 ]
- Smilgin Z, Drozdzik M, Gawronska-Szklarz B, Wojcicki J, Tustanowski S, Gornik W: [Pharmacokinetics of acetaminophen in individuals occupationally exposed to polyvinyl chloride modified with plasticizers]. Med Pr. 1993;44(5):423-9. [8107555 ]
- Griener JC, Msall ME, Cooke RE, Corcoran GB: Noninvasive determination of acetaminophen disposition in Down's syndrome. Clin Pharmacol Ther. 1990 Nov;48(5):520-8. [2146059 ]
- Mohammadi M, Mohebbi MR, Naderi F: CSF Glucose Concentrations in Infants with Febrile Convulsions and the Possible Effect of Acetaminophen. Indian Pediatr. 2003 Dec;40(12):1183-6. [14722369 ]
- Munsterhjelm E, Munsterhjelm NM, Niemi TT, Ylikorkala O, Neuvonen PJ, Rosenberg PH: Dose-dependent inhibition of platelet function by acetaminophen in healthy volunteers. Anesthesiology. 2005 Oct;103(4):712-7. [16192763 ]
- de Morais SM, Uetrecht JP, Wells PG: Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology. 1992 Feb;102(2):577-86. [1732127 ]
- Findlay JW, DeAngelis RL, Kearney MF, Welch RM, Findlay JM: Analgesic drugs in breast milk and plasma. Clin Pharmacol Ther. 1981 May;29(5):625-33. [7214793 ]
- Lifshitz M, Weinstein O, Gavrilov V, Rosenthal G, Lifshitz T: Acetaminophen (paracetamol) levels in human tears. Ther Drug Monit. 1999 Oct;21(5):544-6. [10519453 ]
- Bailey DN: Relative binding of acetaminophen, lidocaine, phenobarbital, phenytoin, quinidine, and theophylline to human tissues in vitro. J Anal Toxicol. 1997 Jan-Feb;21(1):1-4. [9013284 ]
- Gandia P, Bareille MP, Saivin S, Le-Traon AP, Lavit M, Guell A, Houin G: Influence of simulated weightlessness on the oral pharmacokinetics of acetaminophen as a gastric emptying probe in man: a plasma and a saliva study. J Clin Pharmacol. 2003 Nov;43(11):1235-43. [14551178 ]
- McEvoy GK (ed) (2007). American Hospital Formulary Service - Drug Information 2007. Bethesda, MD: American Society of Health-System Pharmacists.
- International Agency for Research on Cancer (2014). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. [Link]
- Beaufort-Jasper Water & Sewer Authority (2008). UL Drinking Water Laboratory. [Link]
- Wikipedia. Acetaminophen. Last Updated 8 August 2009. [Link]
- Drugs.com [Link]
- RxList: The Internet Drug Index (2009). [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|
Down-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|